MDCX NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

Medicus Pharma Ltd. Common Stock · Healthcare · Drug Manufacturers - General

Open interactive chart View report data Download investor PDF
Latest close 0.37 USD
-1.5% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -45.0% below the Trend Line and sits at 4.3% of its 52-week range. The latest completed week returned -1.5%, after a -19.2% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 51/100. Near-term considerations: volume confirmation is below normal; earnings are due in 11d.

Setup score 21 out of 100
Latest Close 0.37 USD 24 Jul 2026
1W Return -1.5% latest completed week
4W Return -19.2% short-term follow-through
12W Return 29.7% quarterly tape
Trend Breadth 0.0% 0 of 52 weeks active
Volume Ratio 0.4x vs 13-week average
What is working
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Next-week expectancy is negative at 31.28% based on similar historical setup states.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -1.5% Latest completed week; four-week move -19.2%. Indicator stack 0/64 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Recent Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 31.28% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 51/100 43 relevant articles in the latest sentiment read. Event risk 11d Next report is scheduled for 10 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -45.0% below the Trend Line and sits at 4.3% of its 52-week range. The latest completed week returned -1.5%, after a -19.2% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.4x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.1412-week average 0.05

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure7/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.14Current proprietary activity-pressure read.
Buy signals2Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -19.2% over four weeks, 29.7% over 12 weeks, and -87.4% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-1.5%
4W-19.2%
12W29.7%
26W-73.0%
52W-87.4%
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.55Latest activity-pressure read.
Pressure change52.2%Four-week change in activity pressure.
Leadership-75.37Latest relative-leadership reading.
RS change-0.6%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 55% Model confidence 52%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength52/100Blend of value, momentum, and quality. Underlying universe rank 49; rank 1 is best.
Value50/100Relative valuation strength. Underlying universe rank 51; rank 1 is best.
Quality49/100Profitability and accounting quality. Underlying universe rank 52; rank 1 is best.
Momentum50/100Medium-term price momentum. Underlying universe rank 51; rank 1 is best.
Growth50/100Revenue and earnings growth. Underlying universe rank 51; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-157.4%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
1/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-
Net share repurchases relative to market value.
Shareholder yield
-
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.2x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment51/100

Weighted news tone is neutral across 43 relevant articles.

5 positive · 38 neutral · 0 negative
Patient CapitalRecent

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

Recent buy signal in the last 8 weeks
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings11dNext report is scheduled for 10 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-87.9%Distance below the 52-week high.
13-week volatility14.2%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher7 of 2619 weeks finished lower.
Best week+40.9%Week of 13 Mar.
Worst week-74.7%Week of 6 Mar.
Latest week-1.5%Week of 24 Jul.

Shape of recent returns

Strong gains6
Modest gains1
Flat weeks0
Modest losses5
Sharp losses14
Recent vol14.2%13-week weekly-return volatility.
Base vol16.7%52-week weekly-return volatility.
Up/down split13/39Count of positive and negative weeks in the 52-week window.
Average skew18.3% / -8.7%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape20/100

Trend, activity pressure, participation, and risk combine to a 20/100 tape read.

 Indicator analysis23/100

Latest 12-week confirmation: trend 0/12, activity pressure 7/12, relative leadership 0/12.

Activity pressure 0.14; No reversal markers Next-Week ExpectancyNegative 31.28%

Next-week expectancy is negative with a 31.28% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors49/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 50 Patient CapitalRecent

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

Recent buy signal in the last 8 weeks Sentiment51/100

Weighted news tone is neutral across 43 relevant articles.

Biogen Inc. (BIIB) stock price, news, quote and history Insiders50/100

No recent insider transaction evidence is stored.

 Earnings11d

Next report is scheduled for 10 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 20260.37 USD-1.5%0.67 USD2.16 USD0.55-75.374.1MOff
17 Jul 20260.38 USD-7.8%0.71 USD2.18 USD0.57-76.358.7MOff
10 Jul 20260.41 USD-2.1%0.76 USD2.20 USD0.59-76.414.0MOff
3 Jul 20260.42 USD-9.1%0.81 USD2.22 USD0.57-76.415.3MOff
26 Jun 20260.46 USD0.1%0.86 USD2.24 USD0.36-74.909.4MOff
19 Jun 20260.46 USD35.5%0.92 USD2.26 USD0.30-76.8616.4MOff
12 Jun 20260.34 USD-3.5%0.97 USD2.28 USD0.13-82.974.2MOff
5 Jun 20260.35 USD-7.7%1.04 USD2.31 USD-0.05-82.4915.1MOff
29 May 20260.38 USD26.3%1.10 USD2.33 USD-0.09-82.4621.5MOff
22 May 20260.30 USD-0.3%1.17 USD2.35 USD-0.39-86.114.7MOff
15 May 20260.30 USD-10.1%1.25 USD2.38 USD-0.67-87.057.2MOff
8 May 20260.34 USD17.4%1.32 USD2.41 USD-0.80-86.6221.1MOff
1 May 20260.29 USD-9.4%1.39 USD2.43 USD-1.00-88.546.4MOff
24 Apr 20260.31 USD-10.4%1.47 USD2.46 USD-1.08-87.7112.3MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.